FDA adds “abnormal behavior” precaution to Tamiflu label

The FDA has added the new precaution to Tamiflu because of more than 100 recent cases of delirium, hallucinations, and other psychiatric behavior in Japanese patients treated with the drug. On the other hand, the FDA acknowledges that stopping Tamiflu treatment can actually harm influenza patients if the virus is the cause of hallucinations and other abnormal behavior. The number of reports of bizarre behavior is increasing.

For the full article.

Lawyer Monthly - Legal Awards Winner
The National Trial Lawyers
Elder Care Matters Alliance
American Association for Justice
Fellow Litigation Counsel of America
Super Lawyers